Qiming ESG | Crafting a New Future from Plastic Waste — Qiming Venture Partners Hosts Upcycling Workshop
This initiative aligns closely with multiple United Nations Sustainable Development Goals (SDGs). Through a hybrid format combining hands-on practice and educational outreach, employees gain immersive understanding of the value of circular economy principles — giving discarded materials a "second life."
Recently, Qiming Venture Partners held a discarded plastic upcycling handicraft workshop at its Beijing and Shanghai offices. The event closely aligned with multiple United Nations Sustainable Development Goals (SDGs), combining hands-on practice with educational sessions to help employees understand the value of circular economy through immersive experiences — giving waste materials a "second life."
Plastic pollution has become an urgent global environmental and health issue. A research report published earlier by The Lancet in the United Kingdom found that plastic pollution poses an "increasingly severe yet insufficiently recognized threat" to human health, causing health-related economic losses of at least $1.5 trillion annually.
At the event, employees gathered at the plastic regeneration workshop to creatively repurpose everyday office waste — plastic bottles, packaging shells, and other discarded materials. Through multiple professional mechanical recycling processes — sorting, cleaning, shredding, and melting — plastic waste that might otherwise have been landfilled or incinerated was transformed into functional and commemorative eco-friendly cultural products. Employees put low-carbon principles into action, achieving a deep integration of creativity and environmental protection.
(Swipe left or right to view event photos)
During the event, a professional team also delivered a themed presentation titled The Past and Present Lives of Plastic for Qiming Venture Partners employees, covering the lifecycle of plastics and recycling technologies. This helped employees recognize the heavy burden plastics place on ecosystems and deepened their understanding of the connection between ecological protection and sustainable lifestyles.
(Swipe left or right to view event photos)
As a signatory to the UN-supported Principles for Responsible Investment (UNPRI), Qiming Venture Partners integrates environmental sustainability into the full investment value chain. For years, the firm has actively practiced corporate social responsibility, launching initiatives such as a monthly volunteer program and paid volunteer leave in recent years, encouraging employees to engage deeply in social welfare activities. Going forward, Qiming Venture Partners will continue exploring diverse scenarios for embedding environmental awareness and promoting the natural integration of circular economy concepts into daily office life and beyond.
Past Highlights
Qiming ESG | Qiming Venture Partners Officially Joins UNPRI | Bilingual
Founded in 2006, Qiming Venture Partners currently manages 11 USD funds and 7 RMB funds, with total assets under management reaching $9.5 billion. Since its inception, the firm has focused on investing in outstanding early- and growth-stage companies in Technology and Healthcare innovation.
To date, Qiming Venture Partners has invested in over 580 high-growth innovative companies, of which more than 210 have listed on the New York Stock Exchange, NASDAQ, Hong Kong Exchanges and Clearing Limited, Shanghai Stock Exchange, and Shenzhen Stock Exchange, or exited through M&A and other means. Over 80 portfolio companies have become recognized unicorns or super-unicorns in their industries.
Many companies in Qiming Venture Partners' portfolio have grown into the most influential players in their respective fields, including Xiaomi (01810.HK), Meituan (03690.HK), Bilibili (NASDAQ:BILI, 09626.HK), Zhihu (NYSE:ZH, 02390.HK), Roborock (688169.SH), UBTECH (09880.HK), WeRide (NASDAQ:WRD), Insta360 (688775.SH), Gan & Lee Pharmaceuticals (603087.SH), Tigermed (300347.SZ, 03347.HK), Zai Lab (NASDAQ:ZLAB, 09688.HK), CanSino Biologics (688185.SH, 06185.HK), Schrödinger (NASDAQ:SDGR), MicroPort EP MedTech (688617.SH), Sanyou Medical (688085.SH), Amoy Diagnostics (300685.SZ), Berry Genomics (000710.SZ), Sinocelltech (688520.SH), Yuanxin Technology, Insilico Medicine, MediLink Therapeutics, LaNova Medicines, Zhipu AI, StepFun, Biren Technology, and others.